The naive question: an antibody is the body's targeting protein, but it grabs one thing. What if a single molecule could grab two things at once? That's a bispecific antibody — and in cancer, the 'two things' are chosen on purpose.
Think of it like a matchmaker with a hand on each party's shoulder. One arm of the bispecific latches onto a marker on a tumor cell. The other latches onto a T-cell, the immune system's assassin. Holding the two together forces an introduction the cancer would rather avoid — the T-cell ends up parked on the tumor and kills it.
Merus's grant US11873338B2 is a concrete example: CLEC12AxCD3 bispecific antibodies. The 'x' in the name is the giveaway — it binds CLEC12A (a marker on certain leukemia cells) and CD3 (found on T-cells). One molecule, two targets, deliberately bridged.
The design space is wide. Roche's publication US20240002546A1 covers a combination using a PD1-LAG3 bispecific and a CD20 T-cell bispecific — bispecifics aimed at immune checkpoints, not just direct killing. And publication US20240398951A1 covers T-cell engagers against a different tumor target.
Here's the 'so what.' A bispecific can do something no single-target antibody can: physically connect two cells that wouldn't otherwise meet. That makes it powerful — and also tricky, because over-activating T-cells has its own dangers. The engineering in the patents is largely about getting that bridge strong enough to work but controlled enough to be safe.
The short version: a bispecific antibody is a molecule with two hands. In cancer, it usually holds a tumor cell in one and an immune cell in the other — and the 2024 patent record is full of variations on which two targets to bridge.